Randomized trial of salbutamol in acute bronchiolitis
Terry P. Klassen, Peter C. Rowe, Terry Sutcliffe, Leland J. Ropp, W. McDowell, Marllyn M. Li
To test whether nebulized salbutamol (albuterol) is safe and efficacious for the treatment of young children with acute bronchiolitis, we enrolled 83 children (median age 6 months, range 1 to 21 months) in a randomized, double-blind clinical trial. Participants received two treatments at 30-minute intervals of either nebulized salbutamol (0.10 mg/kg in 2 ml 0.9% saline solution) or a similar volume of 0.9% saline solution placebo. Outcome measures were the respiratory rate, pulse oximetry, and a clinical score based on the degree of wheezing and retractions. Patients in the salbutamol arm had significantly greater improvement in clinical scores after the initial treatment (p=0.04). There was no difference between the groups in oxygen saturation (p=0.74); patients treated with salbutamol had a small increase in heart rate after two treatments (159±16 vs 151±16; p=0.03). We conclude that salbutamol is safe and effective for the initial treatment of young children with acute bronchiolitis.
The Journal of pediatrics
Dive into the research topics of 'Randomized trial of salbutamol in acute bronchiolitis'. Together they form a unique fingerprint.
Bronchiolitis Medicine & Life Sciences 100%
Albuterol Medicine & Life Sciences 96%
Saline Solution Medicine & Life Sciences 50%
Oximetry Medicine & Life Sciences 16%
Respiratory Sounds Medicine & Life Sciences 14%
Respiratory Rate Medicine & Life Sciences 14%
Klassen, T. P., Rowe, P. C., Sutcliffe, T., Ropp, L. J., McDowell, W., & Li, M. M. (1991). Randomized trial of salbutamol in acute bronchiolitis. The Journal of pediatrics, 118(5), 807-811. https://doi.org/10.1016/S0022-3476(05)80051-4
Randomized trial of salbutamol in acute bronchiolitis. / Klassen, Terry P.; Rowe, Peter C.; Sutcliffe, Terry et al.
In: The Journal of pediatrics, Vol. 118, No. 5, 05.1991, p. 807-811.
Klassen, TP, Rowe, PC, Sutcliffe, T, Ropp, LJ, McDowell, W & Li, MM 1991, 'Randomized trial of salbutamol in acute bronchiolitis', The Journal of pediatrics, vol. 118, no. 5, pp. 807-811. https://doi.org/10.1016/S0022-3476(05)80051-4
Klassen TP, Rowe PC, Sutcliffe T, Ropp LJ, McDowell W, Li MM. Randomized trial of salbutamol in acute bronchiolitis. The Journal of pediatrics. 1991 May;118(5):807-811. doi: 10.1016/S0022-3476(05)80051-4
Klassen, Terry P. ; Rowe, Peter C. ; Sutcliffe, Terry et al. / Randomized trial of salbutamol in acute bronchiolitis. In: The Journal of pediatrics. 1991 ; Vol. 118, No. 5. pp. 807-811.
@article{c525c5168f924519900bd25dad087bd9,
title = "Randomized trial of salbutamol in acute bronchiolitis",
abstract = "To test whether nebulized salbutamol (albuterol) is safe and efficacious for the treatment of young children with acute bronchiolitis, we enrolled 83 children (median age 6 months, range 1 to 21 months) in a randomized, double-blind clinical trial. Participants received two treatments at 30-minute intervals of either nebulized salbutamol (0.10 mg/kg in 2 ml 0.9% saline solution) or a similar volume of 0.9% saline solution placebo. Outcome measures were the respiratory rate, pulse oximetry, and a clinical score based on the degree of wheezing and retractions. Patients in the salbutamol arm had significantly greater improvement in clinical scores after the initial treatment (p=0.04). There was no difference between the groups in oxygen saturation (p=0.74); patients treated with salbutamol had a small increase in heart rate after two treatments (159±16 vs 151±16; p=0.03). We conclude that salbutamol is safe and effective for the initial treatment of young children with acute bronchiolitis.",
author = "Klassen, {Terry P.} and Rowe, {Peter C.} and Terry Sutcliffe and Ropp, {Leland J.} and W. McDowell and Li, {Marllyn M.}",
note = "Funding Information: Whether infants with acute bronchiolitis should be treated with nebulized salbutamol or other B2-adrenergic drugs has been debated for more than 20 years. 1{"}3 Recent work has emphasized the limited validity of pulmonary function tests in wheezing infants, 4{"}6 raising questions about earlier studies that demonstrated either no improvement or a deterioration in respiratory status after the administration of aor ~-adrenergic agents, i; 7-13 The development of a reliable scoring system for infants with bronchiolitis, TM similar to a scoring system that correlates well with tests of pulmonary function in older children with asthma,15 provided a means of reexamining the safety and efficacy of salbutamol with the use of common clinical features of the disease to measure outcome. We report the results of a randomized trial designed to test the hypothesis Supported by grant No. 01288N from the Emergency Services Division, Ministry of Health of Ontario, and by a Career Scientist Award (Dr. Rowe) from the Ministry Of Health of Ontario. Submitted for publication Sept. 21, 1990; accepted Nov. 16, 1990. Reprint requests: Terry P. Klassen, MD, Division of Emergency Medicine, Children's Hospital of Eastern Ontario, 401 Smyth Rd., Ottawa, Ontario K1H 8L1, Canada. 9/25/26840 that nebulized salbutamol would provide greater short-term improvement in respiratory status than a placebo in young children with bronchiolitis.",
journal = "Journal of Pediatrics",
T1 - Randomized trial of salbutamol in acute bronchiolitis
AU - Klassen, Terry P.
AU - Rowe, Peter C.
AU - Sutcliffe, Terry
AU - Ropp, Leland J.
AU - McDowell, W.
AU - Li, Marllyn M.
N1 - Funding Information: Whether infants with acute bronchiolitis should be treated with nebulized salbutamol or other B2-adrenergic drugs has been debated for more than 20 years. 1"3 Recent work has emphasized the limited validity of pulmonary function tests in wheezing infants, 4"6 raising questions about earlier studies that demonstrated either no improvement or a deterioration in respiratory status after the administration of aor ~-adrenergic agents, i; 7-13 The development of a reliable scoring system for infants with bronchiolitis, TM similar to a scoring system that correlates well with tests of pulmonary function in older children with asthma,15 provided a means of reexamining the safety and efficacy of salbutamol with the use of common clinical features of the disease to measure outcome. We report the results of a randomized trial designed to test the hypothesis Supported by grant No. 01288N from the Emergency Services Division, Ministry of Health of Ontario, and by a Career Scientist Award (Dr. Rowe) from the Ministry Of Health of Ontario. Submitted for publication Sept. 21, 1990; accepted Nov. 16, 1990. Reprint requests: Terry P. Klassen, MD, Division of Emergency Medicine, Children's Hospital of Eastern Ontario, 401 Smyth Rd., Ottawa, Ontario K1H 8L1, Canada. 9/25/26840 that nebulized salbutamol would provide greater short-term improvement in respiratory status than a placebo in young children with bronchiolitis.
N2 - To test whether nebulized salbutamol (albuterol) is safe and efficacious for the treatment of young children with acute bronchiolitis, we enrolled 83 children (median age 6 months, range 1 to 21 months) in a randomized, double-blind clinical trial. Participants received two treatments at 30-minute intervals of either nebulized salbutamol (0.10 mg/kg in 2 ml 0.9% saline solution) or a similar volume of 0.9% saline solution placebo. Outcome measures were the respiratory rate, pulse oximetry, and a clinical score based on the degree of wheezing and retractions. Patients in the salbutamol arm had significantly greater improvement in clinical scores after the initial treatment (p=0.04). There was no difference between the groups in oxygen saturation (p=0.74); patients treated with salbutamol had a small increase in heart rate after two treatments (159±16 vs 151±16; p=0.03). We conclude that salbutamol is safe and effective for the initial treatment of young children with acute bronchiolitis.
AB - To test whether nebulized salbutamol (albuterol) is safe and efficacious for the treatment of young children with acute bronchiolitis, we enrolled 83 children (median age 6 months, range 1 to 21 months) in a randomized, double-blind clinical trial. Participants received two treatments at 30-minute intervals of either nebulized salbutamol (0.10 mg/kg in 2 ml 0.9% saline solution) or a similar volume of 0.9% saline solution placebo. Outcome measures were the respiratory rate, pulse oximetry, and a clinical score based on the degree of wheezing and retractions. Patients in the salbutamol arm had significantly greater improvement in clinical scores after the initial treatment (p=0.04). There was no difference between the groups in oxygen saturation (p=0.74); patients treated with salbutamol had a small increase in heart rate after two treatments (159±16 vs 151±16; p=0.03). We conclude that salbutamol is safe and effective for the initial treatment of young children with acute bronchiolitis.
JO - Journal of Pediatrics
JF - Journal of Pediatrics